Skip to main content
. Author manuscript; available in PMC: 2013 May 22.
Published in final edited form as: Int J Radiat Biol. 2011 Dec 20;88(3):277–285. doi: 10.3109/09553002.2012.638359

Figure 3.

Figure 3

Effect of repair capacity on the cytotoxicity of Laromustine. Normal repair-proficient human fibroblasts (●) or fibroblasts with a Fanconi Anemia C mutation (○) were treated with Laromustine for 2 hours and assayed for survival using a clonogenic assay. BRCA2 deficient VC8 cells (□) and the control cells transfected to express BRCA2 (■) were treated for 2 hours with graded doses of Laromustine and assayed for survival using clonogenic assays. Points are mean ± SEM for 3 independent determinations for human cells and 4–6 independent determinations for VC8 cell lines.